Protocol Ledger

NCT05871970 · Phase II · RECRUITING

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

Interventional Phase II clinical trial protocol NCT05871970 sponsored by Protara Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-10-18 Enrollment: 38 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05871970
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)38 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05871970
Protocol FieldVerified Registry Value
NCT IdentifierNCT05871970
Consolidated Lead SponsorProtara Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment38 participants (ESTIMATED)
Registered Start Date2023-10-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI